Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

DRUG5 trials

Sponsors

Gilead Sciences, University of South Florida

Conditions

HIV InfectionsHIV PreventionPre-Exposure Prophylaxis (PrEP)Pre-Exposure Prophylaxis of HIV Infection

Phase 2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Active, not recruitingNCT06101342

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2023-12-13End: 2028-01-01Updated: 2026-08-13

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Active, not recruitingNCT06101329

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2023-11-17End: 2028-01-01Updated: 2026-08-17

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Active, not recruitingNCT06513312

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2024-10-07End: 2028-11-01Updated: 2026-06-15

Phase 4

Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator

Not yet recruitingNCT07901101

University of South FloridaHIV Prevention, Pre-Exposure Prophylaxis (PrEP)

Start: 2026-11-01End: 2028-05-01Target: 50Updated: 2026-10-28

Unknown Phase

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

RecruitingNCT07473778

Gilead SciencesHIV Infections

Start: 2026-03-17End: 2029-04-01Target: 3000Updated: 2026-10-21

Related Papers

Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization.

2026-01-07